COMPOSÉS IMIDAZO[4,5-C]QUINOLIN-2-ONE DEUTÉRÉS ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER

The specification generally relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, where R1 has the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer....

Full description

Saved in:
Bibliographic Details
Main Authors PIKE, Kurt, Gordon, BARLAAM, Bernard, Christophe
Format Patent
LanguageFrench
Published 24.06.2020
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The specification generally relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, where R1 has the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; and kits comprising such compounds and salts.
Bibliography:Application Number: MA20180049884